Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

237.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 237.00
Bid (Size) 94.80 (2)
Ask (Size) 243.08 (2)
Prev. Close 237.00
Today's Range 237.00 - 237.00
52wk Range 204.44 - 261.54
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire

Performance

YTD
+4.24%
+4.24%
1 Month
-2.97%
-2.97%
3 Month
+8.31%
+8.31%
6 Month
+5.57%
+5.57%
1 Year
+4.72%
+4.72%

More News

Read More
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
From United Therapeutics Corporation
Via Business Wire
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Via Benzinga
Earnings Scheduled For February 21, 2024
Via Benzinga
Earnings Outlook For United Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
From United Therapeutics Corporation
Via Business Wire
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
Via InvestorPlace
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
Via InvestorPlace
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings
Via Benzinga
Exposures Product Safety
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
From United Therapeutics Corporation
Via Business Wire
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
Via InvestorPlace
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
Via InvestorPlace
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Liquidia: Court victory the awakening of an industry giant?
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.